February 26th 2013
Representative Scott Holcomb
Capital Office District Office
511-E Coverdell 2306 Briarcliff
Commons NEAtlanta, GA 30334 Atlanta, GA 30345
Regarding: HB 162: Requiring public schools to provide information
concerning human papilloma virus and the
availability of a vaccine against such virus.
Dear Representative Holcomb,
I am a voting citizen in your district, you are my representative. I am concerned about HB 162. I have found the proposed bill requiring public education about HPV that explicitly leads citizens towards a HPV vaccination to be dangerous. The available research regarding HPV, cervical cancer and the HPV vaccination has convinced me 1) the benefits are too small, 2) the risks of the vaccination are too great, and 3) many more people would suffer as a consequence of public education explicitly leading toward increased utilization of this vaccination.
1) The benefits of the HPV vaccination is too small; it is not clinically proven to be effective.
Tomljenovic L, Shaw CA, Spinosa JP. Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe? Curr Pharm Des. 2012 Sep 24. [Epub ahead of print]
From the abstract:
the widespread optimism regarding HPV vaccines long-term benefits appears to rest on a number of unproven assumptions (or such which are at odds with factual evidence) and significant misinterpretation of available data.
clinical trials data have not demonstrated to date that the vaccines have actually prevented a single case of cervical cancer (let alone cervical cancer death), nor that the current overly optimistic surrogate marker-based extrapolations are justified.2) The HPV vaccination risks are too great.
According to research listed below there's actually a 3-6% increased chance of high-risk HPV infections for vaccinated women when compared to unvaccinated women. And according to Merck, the largest HPV vaccine manufacturer, if a woman has been naturally exposed to the HPV strains found in the vaccine she has a 45% increased risk of precancerous lesions if she gets the shot.
Wright TC, Stoler MH, Behrens CM, et
al. The ATHENA human papillomavirus study: design, methods, and
baseline results. Am J Obstet Gynecol 2012;206:46.e1-11.
3) People would suffer on a larger scale from widespread use of the vaccine more than the viral infection itself.
As of January 7th 2013, the Vaccine Adverse Event Reporting System (VAERS) has received the following HPV vaccination reactions:
FDA.gov Gardasil™ HPV Quadrivalent
Vaccine May 18, 2006 VRBPAC Meeting (PDF)
3) People would suffer on a larger scale from widespread use of the vaccine more than the viral infection itself.
As of January 7th 2013, the Vaccine Adverse Event Reporting System (VAERS) has received the following HPV vaccination reactions:
130 reports of death
904 reports of disability
518 life-threatening adverse events
10,225 emergency room visits
2,809 hospitalizations
This is an excerpt from the case of an
11 year old Georgia girl who died 4 days after her first HPV
vaccination:
March 31st 2009:
First dose of GARDASIL the patient experienced fever and pain in the
hip after getting the vaccine. [Parents of] the patient sought
medical attention.
April 1st 2009
Patient taken to the ER with Fever, presented with hip pain and
muscle tenderness. Thought to be a viral infection. She was
prescribed pain killers. Sent home.
April 3rd 2009
Came to ER again with a fever of 102''F, body aches, inability to
walk, leg pain, nausea, vomiting, rash and severe muscle aches.
Evening April 3rd - 4th
Not sleeping and acting differently. Transferred to higher level of
care.
April 4th 2009
Emergency care; cardiovascular instability. Patient intubated and
despite extensive resuscitation efforts patient expired. The patient
died on 03-APR-2009.
Final diagnosis; Post-vaccination reaction.
An 11yr old little girl died because
she received a poorly tested, risky vaccine for a common
nonthreatening germ.
Please vote no on HB 162.
Thank you for your time and attention.
Aaron Rossi DC
No comments:
Post a Comment